CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...